Clinical trial
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares…
NCT01029652 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT01029652 |
|---|---|
| Title | Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study |
| Official title | A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week Double-blind Extension Study and an Open-label… |
| Acronym | β-RELIEVED |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Gout |
| Intervention type | Drug |
| Interventions | Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide |
| Enrollment | 230 |
| Start date | Dec 1, 2009 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Dec 10, 2009 |
| Last update posted | Jan 30, 2014 |
| Countries | Australia, Belgium, Canada, Colombia, Estonia, Germany, Guatemala, Latvia, Lithuania, Mexico, Norway, Poland and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: